| Literature DB >> 36107524 |
Geng-Hao Bai1, Ping-Yi Shih2, Shih-Yen Chen2,3,4, Kai-Sheng Hsieh2,5, Cheng-Che Chou2,6, Po-Hao Feng7,8, Shu-Sing Kong2,6, Wen-Chuan Lin2,9, Meng-Che Lu2,10.
Abstract
Coronavirus disease 2019 (COVID-19) patients have distinct clinical features in the pediatric groups. However, there is a paucity of research focused on clinical manifestation within pediatric group in Taiwan. This study is to conduct a retrospective study of the clinical features of COVID-19 in Taiwan pediatric patients. A retrospective study was conducted on pediatric patients (Aged ≤ 18 years) in a Northern Taiwan hospital from May 1st, 2021 to June 30th, 2021. Thirty-eight patients were included from emergency room. They were laboratory confirmed COVID-19 through specimens from nasopharyngeal swab by real-time reverse-transcription polymerase chain reaction (RT-PCR). Data including RT-PCR cycle threshold (Ct) values, clinical and epidemiological features were collected and analyzed. Thirty-eight patients aged from 7-month to 18-year-old were included. The median age of patients was 15-year-old. The patients had sex ratio of 23 males to 15 females. More than half patients were infected from family members. Asymptomatic patients were 47.37%. In the symptomatic patients, fever (34.21%) was the most predominant symptom. Cough, nasal obstruction and sore throat were also common. Asymptomatic children had significantly higher Ct-values than symptomatic children, and diagnosed patients with Ct-values more than 19 were associated with asymptomatic infection (P = .0084). Ct-values higher than 19 were associated with asymptomatic infection, which may be a predictor of pediatric disease severity. Our results highlight the distinct clinical manifestations and outcomes in pediatric COVID-19 patients. Compared to the adults, pediatric patients aged ≤ 18 years with COVID-19 in Taiwan mainly had mild disease.Entities:
Mesh:
Year: 2022 PMID: 36107524 PMCID: PMC9439632 DOI: 10.1097/MD.0000000000030157
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Previous studies that have compared Ct-value or viral load between asymptomatic and symptomatic children, median (IQR); mean (SD).
| Author year | Country | Study period | Age | Swab | Target gene | Asymptomatic | Symptomatic |
| Ct-Value outcome summary | Reference | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n) | Ct-value/viral load | (n) | Ct-value/viral load | |||||||||
| Chu 2021 | Korea | February 18–April 30, 2020 | Mean (range) 9.8 (1–18) | NP | RdRp | 13 | E: 30.3 [28.3–32.2] | 18 | E: 31.8 [29.5–34.3] | 0.49 | •Symptomatic and asymptomatic: No difference |
[ |
| Chua 2021 | Hong Kong | March 12–August 8, 2020 | 8.6 [4.3–11.0] | NP or Saliva | RdRp | 28 | NP: 5.7 [4.3–7.4] | 63 | NP: 6.8 [5.6–8.3] | NP: <0.001 | •Symptomatic < asymptomatic |
[ |
| Chung 2021 | USA | March 23–November 9, 2020 | 7.5 (5.3) | MTB or AN | S gene | 47 | N/A | 76 | Mean difference | 0.02 | •Symptomatic < asymptomatic |
[ |
| Cotugno 2021 | Italy | March–July, 2020 | AS: | NP | RdRp | 15 | N/A | 51 | N/A | 0.004 | •Symptomatic < asymptomatic |
[ |
| Ford 2021 | USA | November 16–December 15, 2020 | 5–8 yrs | AN | ORF1ab | 18 | N: 22.2 [21.6–31.6] | 24 | N: 24.3 [21.4–27.3] | N/A | •Symptomatic and asymptomatic: No difference |
[ |
| Ford 2021 | USA | November 16–December 15, 2020 | 9–12 yrs | AN | ORF1ab | 29 | N: 25.4 [23.2–27.6] | 33 | N: 19.6 [17.8–26.9] | N/A | •Symptomatic < asymptomatic |
[ |
| Huillier 2021 | Switzerland | November 10–March 26, 2021 | 11.8 [9.0–14.3] | NP | E gene | 30 | 4.1 (1.9) [Mean log RNA] | 89 | 5.9 (1.8) [Mean log RNA] | <0.001 | •Symptomatic < asymptomatic |
[ |
| Hurst 2020 | USA | April 7–July 16, 2020 | 10.4 [4.8–16.4] | NP or MTB | E gene | 52 | 3.8 [2.8–6.5] | 126 | 4.1 [3.0–5.5] | 0.56 | •Symptomatic and asymptomatic: No difference |
[ |
| Kam 2021 | Singapore | March 23–April 5, 2020 | 7.7 [0.3–15.8] | NP | E gene | 7 | 36.7 | 10 | 28.6 | 0.02 | •Symptomatic < asymptomatic |
[ |
| Kociolek 2021 | USA | March–July, 2020 | N/A | NP or oropharyngeal | N/A | 339 | Adjusted: 8.6 [2.5–12.2] | 478 | Adjusted:-1.7 [-6.0–4.8] | < 0.0001 | •Symptomatic < asymptomatic |
[ |
| Ollier 2022 | France | January 15–May 28, 2021 | 1.7 [0.4–5.2] | NP | N gene | 11 | N: 29.8 (8.5) | 35 | N: 22.2 (5.8) | 0.002 | •Symptomatic < asymptomatic |
[ |
| Peaper 2020 | USA | March 1–September 26, 2020 | 12.0 [5.0–16.0] | NP or MTB | N/A | 38 | N/A | 44 | N/A | N/A | •Symptomatic and asymptomatic: No difference |
[ |
| Pinninti 2021 | USA | March 24–August 20, 2020 | 9.78 (6.56) | NP, nasal, saliva, or rectal | N gene | 45 | 34 (median) | 57 | 26 (median) | 0.001 | •Symptomatic < asymptomatic |
[ |
| Strutner 2021 | USA | April 1–August 1, 2020 | 7.5 | AN or NP | ORF1ab | 210 | 23.5 (6.9) | 518 | 19.9 (6.3) | <0.001 | •Symptomatic < asymptomatic |
[ |
| Zachariah 2020 | USA | March 14–April 24, 2020 | Infants and 1–21 yrs old | NP | E gene | N/A | N/A | N/A | N/A | N/A | •Age < 1 yr old: Lower than Age 1–21 yrs old |
[ |
Ct, Cycle threshold; AN, Anterior nares; MTB, Middle turbinate; NP, Nasopharyngeal; SD, Standard deviation; IQR, interquartile range; N/A, not applicable; E, envelope; RdRp, RNA-dependent RNA polymerase; N, nucleocapsid; S, spike glycoprotein; ORF1ab, open reading frame 1ab.
Demographic and clinical characteristics of children with SARS-CoV-2 infection (N = 38).
| Characteristic | No (%) |
|---|---|
| Age, yr, median (IQR) | 15 (12–16) |
| Sex | |
| Female, n (%) | 15 (39.5) |
| Male, n (%) | 23 (60.5) |
| Household transmission, n (%) | 24 (63.2) |
| Clinical symptoms | |
| Asymptomatic, n (%) | 18 (47.4) |
| Mild symptomatic, n (%) | 20 (52.6) |
| Fever | 13 (65) |
| Cough | 10 (50) |
| Nasal discharge | 10 (50) |
| Sore throat | 7 (35) |
| Diarrhea | 3 (15) |
| Myalgia | 2 (10) |
| Headache | 2 (10) |
| Dysosmia | 1 (5) |
| Admission rate, n (%) | 3 (7.9) |
The difference of demographic features between asymptomatic and symptomatic children.
| Asymptomatic N = 18, n (%) | Symptomatic N = 20, n (%) |
| |
|---|---|---|---|
| Age (median, IQR) | 15 (14–16) | 13.5 (1–16.25) | .122 |
| 0–11 yrs old | 1 (5.6) | 7 (35) | .045* |
| 12–18 yrs old | 17 (94.4) | 13 (65) | |
| Sex | |||
| Female | 7 (38.9) | 8 (40) | .944 |
| Male | 11 (61.1) | 12 (60) | |
| Transmission from family | 8 (44.4) | 16 (80) | .023* |
| Ct-value, mean (SD) | 22.61 (7.07) | 16.65 (5.61) | .006** |
| CT 6–19 | 5 (27.8) | 15 (75) | |
| CT 20–36 | 13 (72.2) | 5 (25) | |
| Admission | 2 (11.1) | 1 (5) | .595 |
Figure 1.Ct-Value comparison by age and disease severity.